HR 19
116th Congress
House
Health
Administrative law and regulatory procedures
Administrative remedies
Advisory bodies
Appropriations
Biological and life sciences
Business records
Cancer
Chemistry
Child health
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Corporate finance and management
Cosmetics and personal care
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Lower Costs, More Cures Act of 2019
Introduced: December 9, 2019
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 19, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Dec 10, 2019
Referred to the Subcommittee on Health.
Dec 9, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 9, 2019
Introduced in House
Plain-English summary
Lower Costs, More Cures Act of 2019
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.
The bill generally
- limits payment amounts for drugs and biologics under Medicare medical services,
- reduces cost-sharing under the Medicare prescription drug benefit,
- modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
- revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
- establishes several reporting requirements for drug manufacturers with respect to drug prices.
What's happening now
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.